All Stories

  1. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial
  2. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion‐dependent thalassemia
  3. The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron‐carbohydrate administration
  4. Response to Cabantchik and Hershko commentary “Plasma nontransferrin bound iron–nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation”
  5. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
  6. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways
  7. OUP accepted manuscript
  8. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study
  9. Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome
  10. Interaction of Transfusion and Iron Chelation in Thalassemias
  11. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
  12. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin
  13. Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay
  14. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization
  15. Understanding transfusional iron distribution by investigating non-transferrin bound iron generation
  16. The Pathophysiology of Transfusional Iron Overload
  17. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan
  18. Consequences and management of iron overload in sickle cell disease
  19. Superior Vena Cava Occlusion by Cardiovascular Magnetic Resonance
  20. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload